These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 38948465)
1. Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database. Liu R; Liu C; Feng D; Guo T; Wang Y Front Pharmacol; 2024; 15():1414703. PubMed ID: 38948465 [TBL] [Abstract][Full Text] [Related]
2. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study. Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013 [TBL] [Abstract][Full Text] [Related]
3. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database. Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926 [TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of ceftazidime/avibactam based on FAERS database. Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z Infection; 2024 Jun; ():. PubMed ID: 38842750 [TBL] [Abstract][Full Text] [Related]
5. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database. Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377 [TBL] [Abstract][Full Text] [Related]
6. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database. Xu H; Xu N; Wang Y; Zou H; Wu S Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956 [TBL] [Abstract][Full Text] [Related]
7. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS. Rao J; Chen X; Liu Y; Wang X; Cheng P; Wang Z Expert Opin Drug Saf; 2024 Oct; 23(10):1317-1325. PubMed ID: 39021273 [TBL] [Abstract][Full Text] [Related]
8. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103 [TBL] [Abstract][Full Text] [Related]
9. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1). Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199 [TBL] [Abstract][Full Text] [Related]
10. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib. Zhang X; Li R; Li Y; He L; Hou E Cureus; 2024 Aug; 16(8):e67925. PubMed ID: 39328691 [TBL] [Abstract][Full Text] [Related]
11. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database. Zhang Y; Zhou C; Liu Y; Hao Y; Wang J; Song B; Yu J Front Pharmacol; 2024; 15():1472648. PubMed ID: 39376606 [TBL] [Abstract][Full Text] [Related]
12. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database. Ning L; Tian Y; Chen D; Han J; Xie G; Sun J Heliyon; 2024 Sep; 10(18):e37348. PubMed ID: 39309940 [TBL] [Abstract][Full Text] [Related]
14. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS). Tang L; Sun C; Liu W; Wu H; Ding C Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285 [No Abstract] [Full Text] [Related]
15. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS). Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595 [TBL] [Abstract][Full Text] [Related]
16. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database. Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895 [TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data. Li B; Zhang J; Huang A; Chen Y; Wei Q Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350 [TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Liu W; Du Q; Guo Z; Ye X; Liu J Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003 [No Abstract] [Full Text] [Related]
19. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data. Dai Z; Wang G; Zhang J; Zhao Q; Jiang L Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557 [TBL] [Abstract][Full Text] [Related]
20. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system. Zhao J; Tao Y Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]